Mika Derynck
Directeur/Membre du Conseil chez ENLIVEN THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Profil
Mika Kakefuda Derynck is currently working as a Director and Independent Director at Enliven Therapeutics, Inc. and as the Chief Medical Officer at Amunix Pharmaceuticals, Inc. She completed her undergraduate degree at Boston University and her doctorate at Boston University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Mika Derynck
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 23/02/2023 |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 19/01/2022 |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Mika Derynck
| Boston University | Undergraduate Degree |
| Boston University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |